Opus Genetics Data Highlights Potential for Presbyopia Drug, Niche Vision Treatment
Event summary
- Opus Genetics will present data at the 2026 ASCRS Annual Meeting, including full results from Phase 3 VEGA-3 trial for phentolamine ophthalmic solution 0.75% for presbyopia.
- A post-hoc analysis of the MIRA-2 trial evaluating RYZUMVI®’s optical impact will also be presented.
- Data from the LYNX-2 trial, assessing phentolamine ophthalmic solution for visual disturbances in post-refractive surgery patients, will be presented again.
- Viatris is providing funding for an educational symposium on presbyopia correction, complementing Opus Genetics’ scientific program.
The big picture
Opus Genetics is attempting to capitalize on the large and growing market for presbyopia correction, currently addressed primarily by glasses and contact lenses. The Phase 3 data presented at ASCRS represents a key inflection point for the company, as it seeks to establish phentolamine ophthalmic solution as a viable alternative. The partnership with Viatris provides a crucial commercialization pathway, but also introduces dependency risk.
What we're watching
- Commercialization
- The success of Viatris’ commercialization efforts for phentolamine ophthalmic solution will be critical for Opus Genetics’ revenue generation, given the licensing agreement.
- Regulatory Risk
- The supplemental new drug application for presbyopia faces regulatory hurdles, and approval timelines will significantly impact market entry and revenue projections.
- Market Adoption
- The rate at which clinicians adopt phentolamine ophthalmic solution for presbyopia, and the willingness of patients to embrace a pharmacological approach, will determine the drug’s overall market penetration.